



NCPDP Guidance on Non-NCPDP Standards: Inter SDO Process

When developing NCPDP guidance on use of non-NCPDP standards for the pharmacy industry, it is critical that the NCPDP developing group (such as a task group) solicit the input of the authoring group of the standard within the parent SDO. This is to assure that the NCPDP guidance is

- compliant with the intent and directives of the relevant standard/implementation guide, and
- provides for the most effective and reasonable use of the non-NCPDP standard/implementation guide for the pharmacy industry.

The communication of NCPDP will also serve to aid in the identification of additional business requirements for the parent SDO and the establishment of mutually agreed upon standard workarounds to meet those needs until formal changes can be incorporated by the parent SDO.

The technical input and/or review of the NCPDP guidance document by the authoring group of the standard may take place at any time during the development period, but must occur prior to the document being submitted for publication on either the public or members-only portions of the NCPDP website. The requirement for review by the authoring group of the parent SDO applies to:

- guidance documents such as the NCPDP ASC X12N 835 Pharmacy Remittance Advice Template
- FAQ responses based on the use of standards from other SDOs
- White papers dealing with the implementation or use of standards from other SDOs

The NCPDP guidance document is submitted by the staff liaison to the authoring work group in the parent SDO. The staff liaison will append the document to a written (email) request to review for technical accuracy of the guidance and submit it to the SDO liaison. When there is no SDO liaison, the staff liaison will work with the Standardization Co-Chairs to direct the document to the appropriate body. This review is required regardless of whether representatives of the SDO participated in the creation of the document. A reasonable timeline for the review and written (email) response is communicated in the referral along with a statement that non-response is considered approval. A call(s) to discuss the guidance and recommendations for change may be arranged through the SDO liaison.

If the response from the authoring group of the parent SDO indicates that NCPDP is recommending a use that violates the standard, then the guidance must be revised to reflect a compliant implementation. If the guidance does not violate the standard, but the authoring group does not agree with the proposed guidance, the developing NCPDP group should carefully evaluate the recommendations and rationale for that disagreement. Changes may be made at the discretion of the group. If no changes are made, the basis for that decision should be communicated to the authoring group of the parent SDO.

After approval by the NCPDP work group, the final document along with the review response is submitted to the Standardization Co-Chairs for approval to publish.

November 2008

National Council for Prescription Drug Programs
9240 East Raintree Drive
Scottsdale, AZ 85260-7518

Phone: (480) 477-1000
Fax: (480) 767-1042
E-mail: ncdpd@ncdpd.org
http: www.ncdpd.org